Probiodrug AG

Probiodrug is a biopharmaceutical company focused on the development of innovative small molecule drugs for the treatment of neuronal, inflammatory, and autoimmune diseases. In these areas, Probiodrug is focusing on innovative targets with the prospect of first and best in class therapeutics. The Company has a dominant position in the area of glutaminyl cyclase (QC) inhibition, an enzyme central for the pathogenesis of Alzheimer’s disease (AD). In this field, Probiodrug is pioneering a completely novel therapeutic approach. In addition, the Company is pursuing further novel approaches in the area of inflammatory diseases.

The Company was founded in 1997 by Dr Konrad Glund and Prof Dr Hans-Ulrich Demuth and has raised a total of $52 million. In 2007, it acquired Ingenium Pharmaceuticals AG. Probiodrug is located in Halle (Saale), Germany, and operates a subsidiary in Martinsried/Munich, Germany.